Seeking Alpha

Unlike many pharmaceutical deals, which often deliver little, if any, value as anticipated new...

Unlike many pharmaceutical deals, which often deliver little, if any, value as anticipated new treatments fail to materialize, Glaxo's (GSX) Stiefel acquisition looks likely to make money for shareholders. GSK -1.7%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|